顺式-1,3-二氨基环戊烷 | 63486-45-3

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 顺式-1,3-二氨基环戊烷
• 中文别名: 1,3-环戊二胺
• 英文名称: cis-1,3-cyclopentyldiamine
• 英文别名: (1R,3S)-cyclopentane-1,3-diamine；cis-cyclopentane-1,3-diamine；cis-1,3-diaminocyclopentane；cis-Cyclopentan-1.3-diamin；cis-1,2-Cyclopentandiamin；(1S,3R)-cyclopentane-1,3-diamine
• CAS: 63486-45-3
• 化学式: C₅H₁₂N₂
• 分子量: 100.164
• InChiKey: ZQWRZCZEOLZBQF-SYDPRGILSA-N

物化性质

• 沸点：
  172.7±8.0 °C(Predicted)
• 密度：
  0.964±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  顺式-1,3-二氨基环戊烷 在 乙二醇 potassium phosphate 、 copper(l) iodide 、 potassium carbonate 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 50.5h， 生成
  参考文献：
  名称：

  Duplex Molecular Strands Based on the 3,6-Diaminopyridazine Hydrogen Bonding Motif:  Amplifying Small-Molecule Self-Assembly Preferences through Preorganization and Iterative Arrangement of Binding Residues

  摘要：

  Structural parameters obtained through single-crystal X-ray diffraction analysis of the one-dimensional H-bonding motif expressed by 3,6-diaminopyridazine are applied to the design of related monomeric, dimeric, and trimeric duplex molecular strands. The mode of assembly and the interstrand affinity of the oligomers are established in solution by H-1 NMR dilution experiments, isothermal titration calorimetry (ITC), and vapor pressure osmometry. Single-crystal X-ray crystallographic analysis of the dimeric diaminopyriclazine 2a corroborates the intended duplex mode of assembly. Binding free energy per unimer (-DeltaGdegrees/n) increases upon extension from monomer to dimer to trimer, signifying a positive cooperative effect. Micromolar binding affinity (K-d = 1.25 +/- 0.1 muM) was determined for the duplex trimer by ITC in 1,2-dichloroethane at 20degreesC. These data provide further insight into the structural and interactional features of synthetic duplex oligomers required for high-affinity, high-specificity binding and define new recognition elements for use in nanoscale assembly.

  DOI：

  10.1021/ja044566p
• 作为产物：
  描述：

  C₁₃H₁₆N₄O₂ 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以93%的产率得到顺式-1,3-二氨基环戊烷
  参考文献：
  名称：

  [EN] TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES TÉTRACYCLIQUES UTILES COMME INHIBITEURS DE L'INTÉGRASE DU VIH

  摘要：

  本发明涉及公式（I）的四环杂环化合物以及其药用可接受的盐或前药，其中n、X、Y、Z、R1、R2和R3的定义如本文所述。本发明还涉及包含至少一种四环杂环化合物的组合物，以及使用四环杂环化合物治疗或预防HIV感染的方法。

  公开号：

  WO2015039348A1

文献信息

• 具有TRK激酶抑制活性化合物、制备方法、组 合物及用途
  申请人：北京鑫开元医药科技有限公司

  公开号：CN110028507B

  公开（公告）日：2020-09-01

  一种具有TRK激酶抑制活性化合物、制备方法、药物组合物及其用途。所述化合物是具有式I的化合物或其药学上可接受的盐、水合物、溶剂化物、同位素化合物。本发明的上述化合物能够作为药物组合物的主要成分，通过抑制TRK激酶活性达到治疗肿瘤目的，可以通过向需要此种治疗或预防的患者给予治疗有效量的一种或则多种本发明化合物或其药用盐、立体异构体或互变异构体达到治疗的目的。所述治疗的肿瘤选自乳腺癌、皮肤癌、膀胱癌、卵巢癌、肺癌等常见癌症。
• Bio-based synthesis of cyclopentane-1,3-diamine and its application in bifunctional monomers for poly-condensation
  作者：Christian A. M. R. van Slagmaat、Jurrie Noordijk、Luciano G. Monsegue、Siri Mogensen、Darya Hadavi、Peiliang Han、Peter J. L. M. Quaedflieg、Gerard K. M. Verzijl、Paul L. Alsters、Stefaan M. A. De Wildeman

  DOI：10.1039/d1gc02372a

  日期：——

  oxime hydrogenation of CPDX over Rh/C to afford the desired CPDA. In addition, diastereomerically pure cis- and trans-isomers of CPDA were reacted with (A) bio-based lactones, and (B) 5-(hydroxymethyl)furfural (HMF) to synthesize novel bifunctional diol monomers with internal amide and imine groups, respectively. Monomer 5, derived using γ-valerolactone (GVL), was successfully applied in the synthesis

  本工作建立了一条以半纤维素为原料合成环戊烷-1,3-二胺（CPDA）的新型绿色路线。通过多次探索和优化，发现单一成功的多步合成包括：（1）糠醇的 Piancatelli 重排为 4-羟基环戊-2-烯酮（4-HCP），（2）高度改进的4使用 Ru Shvo 催化剂将-HCP转化为环戊烷-1,3-二酮 ( CPDO )，(3) CPDO转化为环戊烷-1,3-二肟 ( CPDX )，以及 (4) CPDX在 Rh/ C 以提供所需的CPDA。此外，非对映体纯CPDA 的顺式和反式异构体与 (A) 生物基内酯和 (B) 5-（羟甲基）糠醛 (HMF) 反应，分别合成具有内部酰胺和亚胺基团的新型双官能二醇单体。使用 γ-戊内酯 (GVL) 衍生的单体5已成功应用于聚氨酯的合成。
• Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors
  作者：Ulrich Grädler、Michael Busch、Birgitta Leuthner、Michael Raba、Lars Burgdorf、Martin Lehmann、Nina Linde、Christina Esdar

  DOI：10.1016/j.bmcl.2020.127551

  日期：2020.11

  Triazolo[4,5-d]pyrimidin-5-amines were identified from kinase selectivity screening as novel ERK3 inhibitors with sub-100 nanomolar potencies in a biochemical assay using MK5 as substrate and with an attractive kinase selectivity profile. ERK3 crystal structures clarified the inhibitor binding mode in the ATP pocket with impact on A-loop, GC-loop and αC-helix conformations suggesting a potential structural link towards MK5 interaction via the FHIEDE motif. The inhibitors also showed sub-100 nM potencies in a cellular ERK3 NanoBRET assay and with excellent correlation to the biochemical IC₅₀s. This novel series provides valuable tool compounds to further investigate the biological function and activation mechanism of ERK3.
• Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors
  作者：Vladimir Simov、Sujal V. Deshmukh、Christopher J. Dinsmore、Fiona Elwood、Rafael B. Fernandez、Yudith Garcia、Craig Gibeau、Hakan Gunaydin、Joon Jung、Jason D. Katz、Brian Kraybill、Blair Lapointe、Sangita B. Patel、Tony Siu、Hua Su、Jonathan R. Young

  DOI：10.1016/j.bmcl.2016.02.035

  日期：2016.4

  The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, non-receptor tyrosine kinases whose activities have been associated in the literature and the clinic with a variety of hyperproliferative diseases and immunological disorders. At the onset of the program, it was hypothesized that a JAK1 selective compound over JAK2 could lead to an improved therapeutic index relative to marketed non-selective JAK inhibitors by avoiding the clinical AEs, such as anemia, presumably associated with JAK2 inhibition.During the course of the JAK1 program, a number of diverse chemical scaffolds were identified from both uHTS campaigns and de novo scaffold design. As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chemical series. Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966. (C) 2016 Elsevier Ltd. All rights reserved.
• [EN] TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TÉTRACYCLIQUES UTILES COMME INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2015039348A1

  公开（公告）日：2015-03-26

  The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

  本发明涉及公式（I）的四环杂环化合物以及其药用可接受的盐或前药，其中n、X、Y、Z、R1、R2和R3的定义如本文所述。本发明还涉及包含至少一种四环杂环化合物的组合物，以及使用四环杂环化合物治疗或预防HIV感染的方法。